The revised indication is based on recent findings from a prespecified interim analysis showing little benefit in patients whose tumors do not express PD-L1.
Trastuzumab deruxtecan (T-DXd) provided sustained clinically meaningful improvement versus physician’s choice of treatment (TPC) for patients with advanced breast cancer and low HER2 expression.
An antibody-drug conjugate given concurrently with stereotactic radiotherapy to treat brain metastases may increase patients risk for symptomatic radiation necrosis, a study suggests.
Histologic analysis did not sufficiently predict treatment response to certain medications, but methods involving gene expression and transcriptome analysis may be more promising.